<div>
  <ul>
    <li>
      <p>
        California-based AI biopharmaceutical company Fountain Therapeutics has raised USD 15 million in a Series A-2 funding round, bringing the total Series A funds to USD 26 million (the Series A-1 round closed in May 2020). New investors Eli Lilly and Company, Alexandria Venture Investments, and R42 Group joined the existing investors from the previous round.&nbsp;
      </p>
    </li>
  </ul>
  <ul>
    <li>
      <p>
        The proceeds will be directed towards further developing its AI platform that attempts to treat age-related chronic degenerative diseases by reversing cellular age and growing its team, as it plans to further advance its product pipeline.&nbsp;
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.globenewswire.com/news-release/2021/11/18/2337328/0/en/Fountain-Therapeutics-Announces-15-Million-Series-A-2-Financing.html">
      Globe Newswire
    </a>
  </p>
  <p>
    <a href="https://www.medicaldesignsourcing.com/fountain-therapeutics-closes-15-million-in-series-a-2-financing/">
      Medical Design Sourcing
    </a>
  </p>
</div>


All Updates

Fountain Therapeutics raises USD 15 million Series A-2